HUM stock forecast, quote, news & analysis

Key Takeaways

• Humana reported that 95% of its Medicare Advantage members are now enrolled in plans rated at least four stars for 2027, a sharp rebound from roughly 20%–25% in recent years.
• The improved ratings restore Humana's eligibility for government quality bonus payments, a central pillar of the company's multi-year margin recovery plan.
• Shares surged to a 52-week high on the news, building on analyst upgrades and price-target increases from firms including Oppenheimer and Cantor Fitzgerald.
• Management reaffirmed its full-year 2026 adjusted earnings guidance of at least $9.00 per share.
• The company expects a portion of the 2028 benefit to fund one-time investments and returns to shareholders.

Current Market Snapshot

Humana shares rallied sharply in the most recent session after the Centers for Medicare and Medicaid Services (CMS) published final 2027 Medicare Advantage Star Ratings. The stock jumped by a double-digit percentage intraday, touching a 52-week high and reflecting renewed investor confidence in the insurer's quality-improvement turnaround. The advance stands in contrast to peers, several of which posted declines in their own star-ratings results.

The move reinforces a broader shift in sentiment across the managed-care sector, where star ratings translate directly into bonus revenue and competitive positioning. For Humana, the results mark a decisive step away from the ratings setback of two years ago, when the share of members in four-star-or-better plans fell from more than 90% to roughly 25%. Investors now appear to be pricing in a more durable earnings recovery for the company.

Humana (HUM) Business Overview and Competitive Position

Humana Inc. is one of the largest U.S. health insurers, with Medicare Advantage as its flagship business. The company offers Medicare Advantage plans, Medicare Supplement products, and standalone prescription drug plans to individuals and employer groups. It also serves Medicaid beneficiaries and military families through the TRICARE program and operates a pharmacy benefit management business.

Through its CenterWell segment, Humana provides direct healthcare services including primary care, home health, and hospice care, positioning the company to capture value across the care-delivery spectrum. Membership is concentrated in states such as Florida, Texas, and Ohio. Investors follow the stock closely because of its outsized exposure to government-sponsored programs, where regulatory changes, reimbursement rates, and star-ratings outcomes have an outsized impact on revenue and margins relative to diversified competitors.

Recent Developments Driving HUM

The dominant catalyst was the October 2026 release of final 2027 Medicare Advantage Star Ratings by CMS. Humana disclosed that 95% of its members are now in plans rated four stars or higher, up from roughly 20% for 2026, and that 42% of members are in plans rated 4.5 stars or higher. The results exceeded Humana's top-quartile performance goal and beat Wall Street expectations. Oppenheimer noted the difference could account for roughly $3.6 billion in revenue, translating to a meaningful earnings contribution if not passed through to bids.

The ratings recovery reinstates Humana's eligibility for quality bonus payments across a large share of its membership. Higher-rated plans also tend to attract and retain more members, supporting both revenue growth and the company's stated commitment to unlocking earnings potential by 2028.

Analyst activity has been supportive. Oppenheimer raised its price target on Humana to $475 from $405 while maintaining an Outperform rating, calling Humana the "biggest winner" from the new ratings. Separately, Cantor Fitzgerald upgraded the stock to Overweight from Neutral with a $460 price target, citing anticipated improvements in star scores. Management also reaffirmed its 2026 adjusted earnings guidance of at least $9.00 per share, consistent with guidance issued in July 2026.

Trending AI Robots

For traders seeking a data-driven approach to opportunities like Humana's recent move, Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section. The featured robots vary in strategy, holding timeframe, and performance metrics, giving users a range of approaches to evaluate. The page serves as a starting point for exploring how algorithmic systems interpret shifting market conditions. Investors interested in systematic trading can review the available bots to see which strategies currently align with their objectives.

2026 Outlook and What Investors Should Watch

Looking ahead, several factors will shape Humana's trajectory. First, investors will monitor the company's ability to convert the star-ratings improvement into sustained earnings growth, including how much of the 2028 benefit is retained versus reinvested. Management has indicated it will share details on the level and expected use of a one-time 2028 benefit once it has greater visibility into competitive dynamics and the rate and regulatory environment.

Second, Humana has scheduled a virtual investor update for December 10, 2026, to provide a mark-to-market against the framework laid out at its 2025 Investor Day, including initiatives expected to support earnings growth through 2028. Third, broader Medicare Advantage industry headwinds remain relevant, including medical cost trends, utilization levels, reimbursement-rate decisions, and competitive pressures from peers such as UnitedHealth, CVS Health, Elevance Health, and Centene. Finally, quarterly results and any updates to 2026 and 2028 guidance will be closely watched as the company completes its financial close for the period ended September 30, 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations